Abaloparatide (CAS 247062-33-5) is a high-purity parathyroid hormone-related protein (PTHrP) fragment peptide API, a potent PTH1 receptor agonist. With a precise 34-amino acid sequence, it mimics the biological activity of parathyroid hormone (PTH), stimulating osteoblast differentiation and activity while inhibiting osteoclast-mediated bone resorption. This dual mechanism leads to a net increase in bone mass and strength, making it a breakthrough therapy for osteoporosis.
Produced under strict GMP standards, this API ensures consistent purity (≥98%) and biological activity, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for the treatment of postmenopausal osteoporosis and other conditions characterized by low bone density, catering to the needs of pharmaceutical manufacturers and research institutions in the field of orthopedics and endocrinology.
Its unique ability to promote bone formation without the systemic side effects associated with PTH administration makes it a preferred choice for clinical use. Abaloparatide delivers reliable therapeutic benefits with a favorable safety profile, supporting the development of effective treatments for skeletal disorders.
